FTC Tells Medtronic To Sell Intersect ENT Subsidiary To Avoid Monopoly
Executive Summary
The move removes all regulatory roadblocks to Medtronic’s $1.1bn acquisition of Intersect ENT, which was announced in August 2021.
You may also be interested in...
Medtronic Bolsters Sinus Portfolio With $1.1Bn Intersect ENT Buyout
Medtronic announced plans to acquire Intersect ENT, adding its sinus implants to Medtronic's portfolio of devices used by surgeons in treating chronic rhinosinusitis.
Watchdog Calls On FDA To Set Policy For Use Of Unauthorized Tests In Public Health Emergencies
The US Government Accountability Office reviewed how the FDA reviewed and monitored COVID-19 tests during the pandemic and found room for improvement. One particular concern was the lack of a straightforward policy on when enforcement discretion would be used.
FDA Allows 510(k)s For HIV Diagnostics
The tests are being moved to class II, special controls, after the agency determined that would be enough to ensure device safety and efficacy.